The FDA-approved Janus kinase inhibitors (JAKi) (i.e., jakinibs) are used to diminish the effects from STAT3 activation and to control progression of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases [107, 108]. The gene discussed is STAT3; the disease is Parkinson disease.